Guizhou Xinbang Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002390.SZ

Guizhou Xinbang Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2023: 4.19%

Guizhou Xinbang Pharmaceutical Co., Ltd. Return on Equity (ROE) is 4.19% for the year ending December 31, 2023, a 27.19% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Guizhou Xinbang Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was 3.30%, a -41.66% change year over year.
Guizhou Xinbang Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was 5.65%, a 60.12% change year over year.
Guizhou Xinbang Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was 3.53%, a -27.78% change year over year.
Guizhou Xinbang Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was 4.89%, a 118.72% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Shenzhen Stock Exchange: 002390.SZ

Guizhou Xinbang Pharmaceutical Co., Ltd.

CEO	Ms. Lingzhong Kong
IPO Date	April 16, 2010
Location	China
Headquarters	Intersection of Hangtian Avenue and Xint
Employees	5,149
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.

Key trends

Past 5 years